+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Axovant's stock is crashing after failing a key drug trial

Sep 26, 2017, 18:28 IST

NIH

Advertisement

Shares of Axovant are plummeting after the company had failed a key late-stage trial for its Alzheimer's drug.

Shares are down 75.59% in early trading on Tuesday at $5.92 a piece. Axovant closed Monday's trading session at $24.25.

The pharmaceutical company, founded by 32-year-old Vivek Ramaswamy, was trading for just a tenth of its previous day's value at one point Tuesday morning.

Axovant is the latest company to fail a notoriously hard Alzheimer's drug trial. Drugs hoping to treat the disease or its symptoms have failed to pass clinical trials 99% of the time.

Advertisement

Axovant's drug, intepirdine, hoped to stop the decline of cognitive function and ability to perform daily tasks in those with Alzheimer's. The company combined intepirdine with donepezil, an existing Alzheimer's drug, hoping to improve the effectiveness of donepezil.

The company will continue to look for other uses of its intepirdine drug.

Shares were up 113% this year before the failed drug trial. Axovant is now down 52.18% in 2017.

Click here to watch shares of Axovant trade in real time...

Markets Insider

Advertisement

NOW WATCH: Making money isn't all that matters to investors

Next Article